Overview: Abacus Life reported a solid top-line expansion in QQ4 2024 with revenue of $33.21 million, up 40.16% year over year, and a gross margin of 88.8%. However, the quarter delivered a material bottom-line hit, with net income of -$18.26 million and negative EBITDA of -$7.61 million, underscoring ongoing profitability challenges despite scale in the life settlements and related servicing portfolio. Management commentary in the reported materials (where disclosed) centered on portfolio execution and capital deployment, but no formal forward-looking guidance was provided. Cash flow from operations was robust at $64.8 million, aided by favorable working capital dynamics and significant non-cash charges, yet free cash flow remained negative at -$92.1 million due to working capital needs and stock-based compensation. The balance sheet displays a solid liquidity position (cash $131.9 million; current assets $159.6 million; cash ratio ~2.1x) but an elevated debt load (total debt $385.9 million; net debt $254.0 million) that constrains near-term leverage flexibility. The company also issued a sizable amount of common stock during the period, indicating dilution risk and a financing strategy that prioritizes liquidity. This report synthesizes the QQ4 2024 results with available data to provide a forward-looking view for investors.